Directorate change

Summary by AI ^BETAClose X

Anchor Hanover Group confirms Rachael Shimmin commenced her role as Chief Executive Officer on January 19, 2026, and was appointed to the Board on January 20, 2026, as part of its unitary board structure which includes nine Non-executive Directors and two Executive Directors. This appointment follows the initial announcement in November 2025. The company also has £450,000,000 2 per cent Secured Sustainability Bonds due 2051 outstanding.

Disclaimer*

Anchor Hanover Group

21 January 2026

APPOINTMENT OF CHIEF EXECUTIVE OFFICER TO THE BOARD

Anchor Hanover Group

21 January 2026

Appointment of Chief Executive Officer to the Board

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM AUSTRALIA, NEW ZEALAND, SOUTH AFRICA, JAPAN, CANADA OR SWITZERLAND OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

Anchor Hanover Group (the Issuer) £450,000,000 2 per cent Secured Sustainability Bonds due 2051 (ISIN XS2349738190).

In November 2025, the Issuer announced the appointment of Rachael Shimmin as Chief Executive Officer. The Issuer is pleased to confirm that Rachael commenced her appointment on 19 January 2026 and was appointed to the Board on 20 January.

Anchor operates a unitary board structure with nine Non-executive Directors and two Executive Directors, being the Chief Executive Officer and the Chief Financial Officer.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END